Datura

# Research Output: Datura

## Botanical Identity

**Accepted taxonomy:** *Datura stramonium* L. (Linnaeus, 1753) is the type species and most widely distributed representative of the genus *Datura*, family **Solanaceae** (nightshade family). Phylogenetic analysis based on 68 protein-coding genes from the chloroplast genome places *Datura* as a sister clade to *Solanum* within the Solanaceae [Ref 6]. The genus is classified in the tribe Datureae.

**Common names:** Jimson weed (from Jamestown, Virginia — site of a documented 1676 mass poisoning of British soldiers); thorn apple (from the spiny capsular fruit); Angel's trumpet (from the large, trumpet-shaped flowers — note: this name is also applied to *Brugmansia* spp., a closely related genus); loco seed (for hallucinogenic properties); apple of Peru (indicating American origin) [Ref 1].

**Genus diversity:** The genus *Datura* comprises multiple recognized species. The Egyptian flora alone encompasses D. *innoxia*, *D. ferox*, *D. metel*, and three forms of *D. stramonium* (*stramonium*, *tatula*, and *inermis*) [Ref 24]. The taxonomic status of the genus remains debated, with recent biosystematic revision revealing novel tropane alkaloids in certain species for the first time [Ref 24].

**Native range and distribution:** *D. stramonium* is native to the Americas (the epithet "apple of Peru" in historical naming reflects this origin) [Ref 1]. It has since naturalized globally and is now considered a cosmopolitan weed, growing in disturbed habitats, roadsides, farmland edges, and waste areas across temperate and subtropical regions of all continents. It is both wild-harvested and an agricultural contaminant; it is not deliberately cultivated for commercial alkaloid production (which instead uses *Atropa belladonna* and related species) [Ref 1, Ref 3].

**Morphological notes and misidentification risks:** *Datura* plants are erect annual herbs (rarely shrubby) typically 0.5–1.5 m tall. Leaves are large, irregularly lobed; flowers are large, white or pale violet trumpets; fruits are spiny ovoid capsules containing numerous dark seeds — the source of the highest alkaloid concentrations. *D. stramonium* (white flowers) is distinguished from *D. stramonium* var. *tatula* (purple-tinged flowers and stems). Misidentification risk: young *Datura* plants can be confused with edible species (e.g., *Solanum* spp. vegetables); seeds can contaminate grain harvests of similar-looking crops. *Brugmansia* spp. (angel's trumpets) are closely related woody shrubs with pendulous flowers containing the same alkaloids — they share overlapping risk profiles.

**Cultivation status:** Primarily wild-harvested (weed in agricultural fields and disturbed ground). Not deliberately cultivated for recreational or medicinal use, though it grows freely where seeds fall.

**Discrepancy with seed data:** The brief listed Family, Genus/species, Native range, and Cultivation status all as "(no seed data)." Research confirms: Family = Solanaceae; Genus/species = *Datura stramonium* L. (with multiple related species); Native range = Americas (now cosmopolitan weed); Cultivation status = wild-harvested / agricultural contaminant.

---

## Alkaloid / Cannabinoid Profile

**Primary alkaloids:** All parts of *Datura* plants contain tropane alkaloids, with **hyoscyamine** (L-hyoscyamine), **scopolamine** (L-hyoscine), and **atropine** (DL-hyoscyamine racemate) as the dominant constituents [Ref 1, Ref 3]. Minor alkaloids include **norhyoscyamine** (a cytochrome P450-mediated derivative identified by Zhang et al. 2023 [Ref 23]), **anisodamine**, and trace apotropane alkaloids. Other phytochemical classes present include tannins, flavonoids, cardiac glycosides, withanolides, and phenolics [Ref 3, Ref 26].

**PubChem chemical identity:**
- Scopolamine (L-scopolamine / hyoscine): CID 3000322; MF C₁₇H₂₁NO₄; MW 303.35 g/mol; InChIKey STECJAGHUSJQJN-USLFZFAMSA-N
- L-Hyoscyamine: CID 154417; MF C₁₇H₂₃NO₃; MW 289.4 g/mol; InChIKey RKUNBYITZUJHSG-VFSICIBPSA-N
- Atropine (racemate): CID 174174; MF C₁₇H₂₃NO₃; MW 289.4 g/mol; InChIKey RKUNBYITZUJHSG-PJPHBNEVSA-N

**Quantified concentrations by organ (Jakabová et al. 2012, LC-MS; four Datura taxa grown under identical conditions) [Ref 4]:**
- Alkaloid distribution: hyoscyamine (measured as atropine) and scopolamine occur in **all plant organs** — leaves, flowers, stems, and seeds
- *D. stramonium*: atropine (hyoscyamine) dominant over scopolamine across all organs
- *D. stramonium* var. *tatula*: highest hyoscyamine levels among all four taxa examined
- *D. innoxia*: highest scopolamine concentrations in all organs examined
- *D. metel*: lowest scopolamine levels
- **Seasonal variation:** Summer samples had significantly higher scopolamine than autumn samples (both stems and leaves); seasonal variation constitutes a major source of batch-to-batch potency variability [Ref 4]

**Concentrations reported in dried plant material:** *Naude et al. 2005* [Ref 16, see below] reported *D. stramonium* hay containing 0.15% m/m hyoscyamine and 0.16% m/m scopolamine by mass; *D. ferox* hay contained only scopolamine at 0.11% m/m [Ref PMID 16108531 — cattle poisoning study]. Seeds are known to be most alkaloid-rich; Erowid/Asthmador data: a commercial Datura-based anti-asthmatic mixture (Asthmador) contained approximately 4.5% atropine and 50.4% scopolamine by weight of total alkaloid content [Ref 25]. **FLAG: specific HPLC concentration values (mg/g dry weight) for seeds from published studies were not retrieved in this research pass. The Jakabová 2012 paper contains quantitative data but full-text values are not available in the abstract. Flag for generation agent to locate specific numeric values if possible.**

**Biosynthetic pathway:** Hyoscyamine and scopolamine share a conserved biosynthetic pathway in *D. stramonium* and *A. belladonna* [Ref 23]. The enzyme hyoscyamine 6β-hydroxylase (H6H) — a 2-oxoglutarate-dependent dioxygenase — converts hyoscyamine first to 6β-hydroxyhyoscyamine (anisodamine) and then epoxidizes it to scopolamine [Ref 7, Ref 23]. A distinct cytochrome P450 converts hyoscyamine into norhyoscyamine [Ref 7]. These alkaloids are WHO-classified essential medicines (used as antispasmodics and antiemetics) [Ref 17].

**Preparation method effects on constituent ratios:**
- **Oral ingestion** (raw seeds, plant material, tea): all alkaloids extracted; hyoscyamine and scopolamine both active
- **Acidic/alcoholic extraction** (e.g., homemade wine): alcohol combined with low pH dramatically increases scopolamine extraction — the "moon flower wine" case showed 29 mg scopolamine/mL (total dose ~435 mg from 15 mL ingested) [Ref 12]
- **Smoking/inhalation** (historical anti-asthmatic cigarettes; leaves smoked): alkaloids volatilize and are absorbed via pulmonary route; onset is faster than oral; atropine/scopolamine inhaled directly
- **Decoctions/teas**: water extracts alkaloids; precise concentration depends on soak time, temperature, plant part used — highly variable
- **Note:** Atropine (the racemate DL-hyoscyamine) is produced from hyoscyamine by racemization during drying, processing, and extraction — fresh plant material contains predominantly the L-isomer; processed material contains increasing amounts of the D-isomer [Ref 3]

---

## History & Ethnobotany

**First scientific description:** *Datura stramonium* was formally described by Carl Linnaeus in *Species Plantarum* in 1753. The genus name *Datura* is believed to derive from the Sanskrit word *dhattura* (used in Indian traditional medicine). The epithet *stramonium* derives from Medieval Latin for jimsonweed.

**Origin of the name "jimsonweed":** The name is a corruption of "Jamestown weed," derived from the 1676 poisoning incident in Jamestown, Virginia, in which British soldiers sent to suppress Bacon's Rebellion were incapacitated after eating *Datura* in a stew — reportedly spending 11 days in an altered state. This is one of the earliest documented records of mass *Datura* intoxication in North America [Ref 1, Ref 25].

**Traditional and indigenous use:** *Datura* species have been used across multiple continents for thousands of years:
- **Americas:** Native American groups (including the Chumash, Zuni, and various Plains tribes) used *D. innoxia* and *D. stramonium* in initiatory rituals, vision quests, and shamanistic practices. Preparations were ingested orally or used as poultices. Ritualistic use required careful dose control given the narrow margin between psychoactive and lethal doses. [FLAG: Traditional-use accounts for specific Native American groups were not found in PubMed searches; this information relies on ethnographic literature not retrieved in this session — FLAG for human review.]
- **South America / Andes:** Datura species were combined with mescaline-containing cacti (*Trichocereus* spp.) in Andean traditional medicine contexts [Ref 25]
- **Near East / Europe:** Historical use in Middle Eastern preparations involving cannabis; in medieval Europe, *Datura* (along with *Atropa belladonna*, henbane, and mandrake) was an ingredient in "flying ointments" associated with witchcraft. These preparations exploited transdermal absorption of alkaloids
- **India (Ayurveda):** *Datura metel* is described in Ayurvedic texts (*Sushruta Samhita*, *Charaka Samhita*) as *dhatura*. It was used medicinally for asthma, pain, and fever, and in religious contexts associated with the deity Shiva. Legal and used in religious contexts in India today [Ref 18]. [FLAG: Ayurvedic citations not retrieved from primary literature in this session; flag for human review]
- **Haiti (ethnopharmacology):** Datura (scopolamine) has been documented as a key component of the Haitian "zombie powder," used ethnopharmacologically to induce a zombie-like stupor via anticholinergic delirium. Wade Davis's 1980s ethnobiological research brought this use to wider attention [Ref 20]
- **Africa:** *Datura metel* used in traditional medicine across sub-Saharan Africa for various indications

**Western pharmaceutical history:**
- 19th century: Atropine (racemic hyoscyamine) was isolated from *Atropa belladonna* in 1833; scopolamine isolated in 1888
- Early 20th century: Anti-asthmatic cigarettes containing *Datura stramonium* leaves marketed commercially (e.g., Asthmador brand) — these caused documented anticholinergic poisonings when abused for psychedelic effects [Ref 13]
- 1956: Scopolamine approved as a transdermal system for motion sickness (FDA)
- 2020: Yeast-based biosynthesis of scopolamine and hyoscyamine achieved for the first time [Ref 17]

**Criminal use:** *Datura* has been used criminally as a drug-facilitated incapacitating agent — added to drinks by criminals to stun and rob victims. A documented homicide case involved Datura administered in a drink during a robbery in Asia [Ref 9]. Criminal use exploits the rapid onset of confusion, amnesia, and delirium.

**Regulatory history:** See Legal Status section.

---

## Neuroscience & Mechanism

**Receptor targets:** Hyoscyamine and scopolamine are **competitive antagonists at all five muscarinic acetylcholine receptor subtypes (M1–M5)**. They bind with high affinity, blocking the action of endogenous acetylcholine at both central and peripheral muscarinic sites [Ref 5, Ref 3].

**CNS mechanism:**
- **Scopolamine** has greater CNS penetration than atropine/hyoscyamine (more lipophilic, crosses the blood-brain barrier more readily). At low doses, scopolamine produces sedation, amnesia, and cognitive impairment. At higher doses: delirium, hallucinations (visual, tactile, auditory), and confusion [Ref 5]
- **Hyoscyamine / atropine** produce predominantly peripheral anticholinergic effects at lower doses; at higher doses sufficient for CNS penetration, they produce central effects similar to scopolamine
- The anticholinergic CNS syndrome results from blockade of M1 receptors in the hippocampus and cortex (critical for memory and cognition), M2 receptors in cardiac tissue (vagal brake removal → tachycardia), and M3 receptors in smooth muscle and secretory glands (dry mouth, urinary retention, reduced GI motility) [Ref 3, Ref 19]
- Peripheral manifestations: mydriasis, cycloplegia, tachycardia, reduced secretions, hyperthermia (by blocking cholinergic-mediated sweating), urinary retention, decreased bowel sounds [Ref 2, Ref 19]
- The mnemonic for anticholinergic toxidrome: "blind as a bat" (mydriasis, cycloplegia), "mad as a hatter" (delirium), "hot as Hades" (hyperthermia), "dry as a bone" (anhidrosis, dry mouth), "red as a beet" (flushing), "full as a flask" (urinary retention)

**Pharmacokinetics (scopolamine — primary CNS-active alkaloid) [Ref 5]:**
- **Oral bioavailability:** 3–27% (range; significant first-pass effect; CYP3A4-mediated metabolism in intestinal mucosa)
- **Tmax (oral):** approximately 0.5 h; however, CNS effects and anticholinergic toxicity can appear within 30–60 minutes of ingestion of large doses
- **Half-life:** short plasma half-life (not precisely quantified in the abstract; estimates ~3-4h based on clinical data); duration of toxicity is 12–48 hours in overdose cases [Ref 13, Ref 11], suggesting tissue distribution / sustained absorption from plant material
- **Transdermal (clinical formulation):** 1.5 mg reservoir; Cmax ~100 pg/mL (range 11–240 pg/mL) reached at ~8 h; steady-state maintained over 72 h
- **Metabolism:** CYP3A4-mediated oxidative demethylation; glucuronide conjugation in urine; only ~2.6% excreted unchanged; first-pass effect significant
- **Drug interaction:** Grapefruit juice inhibits intestinal CYP3A4, increasing scopolamine AUC to ~142% of control and significantly increasing bioavailability (range 6–37% vs. 3–27% with water) [Ref 5]
- **Placental transfer:** Scopolamine crosses the placenta readily [Ref 5]
- **BBB penetration:** Good; drives CNS effects

**Pharmacokinetics (hyoscyamine / atropine):**
- Similar chemical structure to scopolamine; atropine (racemate) used extensively in clinical practice
- Less lipophilic than scopolamine; somewhat less CNS penetration
- Rapidly absorbed after oral, sublingual, or intramuscular administration
- Elimination half-life ~2–3 hours
- FLAG: Specific bioavailability values for oral hyoscyamine from plant material (vs. pharmaceutical formulations) were not retrieved in this research pass

**CYP involvement:** CYP3A4 primary; CYP3A inhibition (grapefruit, azole antifungals, macrolide antibiotics) would be expected to increase plasma levels from oral Datura ingestion [Ref 5].

---

## Effects & Dose by Preparation

**Critical preamble:** *Datura* is among the most dangerous hallucinogenic plants. The margin between psychoactive doses and toxic/lethal doses is extremely narrow. Alkaloid content varies dramatically between plant specimens, seasons, and plant parts. There is **no established safe recreational dose**. Every preparation carries genuine fatality risk.

**Preparation 1: Raw seed ingestion**
- Most common recreational route [Ref 2, Ref 14]
- Seeds are most alkaloid-dense plant part; concentrations vary by species and harvest season [Ref 4]
- The 2004 fatal case involved a 19-year-old who ingested an unknown quantity of seeds; blood hyoscyamine 1.1 μg/mL, scopolamine 0.2 μg/mL [Ref 10]
- From 29 cases at Kentucky Poison Center (Rodgers 1993): reported amounts ranged from "a few seeds" to ½ cup; typical symptoms included mydriasis, tachycardia, flushing, hallucinations, agitated behavior/lethargy [Ref 14]
- Onset: 30–60 minutes (oral absorption)
- Peak: 1–4 hours
- Duration: 12–48 hours (cases documented) [Ref 13]
- FLAG: No controlled human dose-finding studies exist. All dose data come from accidental/intentional poisoning case series. Dose values are NOT verified against published human dose-response data.

**Preparation 2: Smoked plant material (leaves)**
- Historical anti-asthmatic cigarettes (Asthmador) contained *D. stramonium* leaves; abused for psychedelic effects [Ref 13]
- 4 patients 17–23 years old developed full anticholinergic syndrome; all had amnesia; symptoms resolved over 12–48 h [Ref 13]
- Onset faster than oral route (pulmonary absorption)
- Same anticholinergic syndrome as oral ingestion

**Preparation 3: Aqueous decoction (tea)**
- Alkaloid extraction into water; concentration highly variable
- Used historically in traditional medicine contexts; documented in poisoning cases
- No published dose-response data for tea preparations

**Preparation 4: Alcohol-based preparations (wine, tincture)**
- Alcohol (and acid pH) dramatically increase alkaloid extraction [Ref 12]
- Homemade "moon flower wine" from *D. suaveolens* (Angel's trumpet): 29 mg scopolamine/mL; 15 mL total = 435 mg scopolamine [Ref 12]
- 435 mg scopolamine is an extraordinary dose — equivalent to roughly 870× the maximum transdermal therapeutic patch dose
- FLAG: No established dose for any preparation. All values derive from accidental poisoning cases.

**Effect profile (consistent across preparations, dose-dependent):**
- **Perceptual:** Visual hallucinations (external hallucinations characteristic — patients commonly cannot distinguish them from reality); object transformations; peripheral misidentification; olfactory and gustatory hallucinations; dreaming enhancement; after-images; double vision; mydriasis causing visual blurring [Refs 1, 3, 11]
- **Cognitive:** Profound delirium; amnesia (typically total or near-total for the intoxication period — patients frequently cannot recall their experiences); confusion; thought disorganization; delusions; language suppression; information processing suppression; suggestibility markedly enhanced [Refs 1, 11, 13]
- **Affective:** Anxiety; paranoia; depression; cognitive dysphoria; emotional suppression [Ref 1]
- **Physical:** Tachycardia; mydriasis; dry mouth; urinary retention; constipation; hyperthermia; flushing; sedation or agitation; dizziness; restlessness; muscle tension; involuntary body movements; seizure threshold reduction [Refs 2, 3, 19]
- **Self/Reality:** Depersonalization; derealization; delusions of sobriety (characteristic — patients may believe they are not intoxicated despite severe delirium) [Ref 3]
- **Duration:** 12–48 hours for full syndrome resolution; some cases extend beyond 48 h [Ref 13]

**Key distinction from classical psychedelics:** Unlike serotonergic hallucinogens (psilocybin, LSD), Datura-induced hallucinations are **indistinguishable from reality** — patients cannot recognize them as unreal. This produces a fully deceptive, amnestic delirium rather than an altered-but-ego-intact experience. This characteristic distinguishes the anticholinergic delirium from serotonergic/dissociative experiences.

---

## Safety & Toxicity

**LD50 data:** No human LD50 has been established. In animal studies, atropine LD50 (oral, mice) is approximately 75–500 mg/kg (species-variable). For humans, an oral dose of ~50 mg atropine sulfate has been described as potentially fatal; there is no established fatal dose for scopolamine [Ref 12]. The highest recorded blood concentrations in a fatal human case were hyoscyamine 1.1 μg/mL and scopolamine 0.2 μg/mL [Ref 10].

**EFSA Acute Reference Dose:** The European Food Safety Authority established a group ARfD for (-)-hyoscyamine and (-)-scopolamine combined at **0.016 μg/kg body weight** (based on decreased heart rate observed in human volunteer studies). Dietary exposure of toddlers could reach up to 7× this ARfD on approximately 11–18% of consumption days from grain contamination alone [Ref 22].

**Fatal cases (selection):**
- 2025 (Vivares et al.): 58-year-old male died after accidental ingestion of meal contaminated with Solanaceae plant material. Atropine and scopolamine found in all postmortem matrices including vitreous humor. First documented accidental foodborne fatality [Ref 8]
- 2004 (Boumba et al.): 19-year-old intentionally ingested seeds for hallucinogenic effects; found dead. Blood: hyoscyamine 1.1 μg/mL, scopolamine 0.2 μg/mL — highest concentrations on record at time of publication [Ref 10]
- 2016 (Le Garff et al.): 35-year-old homicide victim; Datura added to drink by a guide. Death from cardiac arrhythmia secondary to severe anticholinergic syndrome. Alkaloids detected in vitreous humor post-embalming [Ref 9]

**Adverse events series:**
- Swiss Toxicology Center 1966–1994 (Jaspersen-Schib et al.): 17 severe *D. stramonium* intoxication cases among 135 severe plant poisonings reviewed. All 17 had anticholinergic syndrome; 12 had psychosis; 2 had coma [Ref referenced from OpenAlex W2301332286, PMID 8711457]
- Rodgers & Von Kanel 1993: 29 cases over 7 years at Kentucky Regional Poison Center, 28/29 intentional abuse; mean age 18.9 years; all had typical mild-moderate anticholinergic symptoms; no fatalities with conservative management [Ref 14]
- Groszek et al. 2000: 7 patients in one month in Kraków; ages 14–27; all had central and peripheral anticholinergic symptoms; 5 treated with physostigmine [Ref 11]

**Psychological risks:**
- Acute psychosis occurs at toxic doses; documented in 12/17 severe Swiss cases [as above]
- Extensive amnesia is typical — patients rarely remember their experience
- Residual anxiety, paranoia, and dysphoria may persist after resolution of acute delirium
- Risk of accidental self-harm or accidents during delirious state is substantial
- Repeated recreational use patterns are uncommon (the extreme unpleasantness of the delirium and amnesia discourages redosing), but the brief seed mentions "mildly addictive" — evidence base for this claim is weak

**Herb–drug interactions:**
- **Additive anticholinergic burden (most important interaction):** Concurrent use with any anticholinergic medication (tricyclic antidepressants, antihistamines, antipsychotics with anticholinergic properties, antiparkinsonian agents, bladder antimuscarinics, antiemetics) produces additive or synergistic anticholinergic toxicity [Ref 21]. This is a mechanistic/pharmacodynamic interaction. Severity: potentially life-threatening. Evidence basis: pharmacovigilance data (Montastruc 2018 [Ref 21]) and extensive clinical literature on anticholinergic burden
- **CYP3A4 inhibitors** (grapefruit juice, ketoconazole, erythromycin, fluconazole): Would be expected to increase scopolamine/hyoscyamine plasma levels by inhibiting first-pass CYP3A4 metabolism, based on demonstrated grapefruit juice effect (AUC ×1.42) [Ref 5]. Clinical case reports for specific inhibitors with plant-derived Datura exposure not found in this search
- **CNS depressants** (alcohol, benzodiazepines, opioids): Additive CNS depression; alcohol additionally increases alkaloid extraction from plant material [Ref 12]. Pharmacodynamic interaction
- **Physostigmine (antidote):** Acetylcholinesterase inhibitor; reverses central anticholinergic syndrome. Used successfully in multiple case series at doses of 1–6 mg [Refs 11, 19]
- FLAG: All interaction severity assessments are based on pharmacokinetic mechanism (CYP3A4 for grapefruit; pharmacodynamic for additive anticholinergics) and pharmacovigilance data, not controlled clinical trials specifically involving Datura plant exposure

**Tolerance and dependence:**
- Brief data: Tolerance buildup with repeated use; half-life 5 days; full reset 1.5 weeks (source: Curiosity v1 DB — NOT verified against published literature in this session)
- FLAG: No published controlled human studies on tolerance development or dependence liability for *Datura* specifically were found. The anticholinergic class generally has low physical dependence potential. Cholinergic rebound (excessive sweating, GI cramping, bradycardia) has been described upon abrupt cessation of chronic anticholinergic drug use but is not well-documented for Datura specifically
- Psychological dependence: The Curiosity DB notes "mildly addictive with high potential for adverse side effects including psychosis." The extreme unpleasantness of Datura intoxication (amnesia, delirium, terror) makes repeated recreational use unusual — this is documented in the Rodgers 1993 series where self-reported users often did not repeat use [Ref 14]. The 2020 review notes Datura associated with drug use "among teens" who typically do not escalate [Ref 2]

**Contaminant and adulterant risks:**
- **Agricultural contamination:** *Datura* seeds are a well-recognized contaminant of grain crops (buckwheat, millet, quinoa). The EU has regulated Datura seed presence in animal feeds at ≤1000 mg/kg (Directive 2002/32/EC) [Ref 4]. Food contamination cases include mass poisonings from contaminated grain/flour
- **Variable potency:** Alkaloid concentrations vary dramatically by species, organ, season, and growing conditions [Ref 4] — making any preparation intrinsically unpredictable in potency
- **Mislabeling/misidentification:** Commercial preparations (teas, supplements) have occasionally contained undisclosed *Datura* material; forensic testing found contaminated herbal products

**Vulnerable populations:**
- **Elderly:** Heightened sensitivity to anticholinergic toxicity; cognitive impairment may be precipitated at lower doses; falls risk
- **Pediatric:** Children particularly susceptible — even small quantities cause serious CNS symptoms [Ref PMID 25341608 — pediatric case report] ; children accidentally exposed through ingestion of attractive plant parts
- **Cardiac disease:** Tachycardia and arrhythmia risk elevated
- **Glaucoma (angle-closure):** Mydriasis can precipitate acute angle-closure glaucoma crisis
- **Urinary obstruction / BPH:** Risk of acute urinary retention
- **Pregnancy:** Scopolamine crosses placenta; avoid in pregnancy [Ref 5]
- **Psychiatric illness:** May precipitate acute psychosis or worsen existing conditions
- **Users of anticholinergic medications:** As above under drug interactions

---

## Harm Reduction

**Emergency response:** Anticholinergic toxidrome is a medical emergency. Treatment includes:
- Supportive care: cooling for hyperthermia; monitoring cardiac rhythm; IV fluids; urinary catheterization if retention
- Activated charcoal if oral ingestion within 1 hour and airway is protected [Ref 19]
- Benzodiazepines for agitation and seizures [Ref 19]
- **Physostigmine** (acetylcholinesterase inhibitor): Specific antidote for severe central anticholinergic syndrome; doses of 1–6 mg IV have been used successfully [Refs 11, 19]; must be administered in monitored setting due to risk of cholinergic excess
- Contact Poison Control immediately

**Identification:** *Datura* plants are identifiable by their distinctive large trumpet-shaped white or pale violet flowers, large irregularly lobed leaves with unpleasant odor when crushed, and spiny ovoid capsular fruit. Seeds are flat, dark brown/black, kidney-shaped. Any preparation from an unidentified plant carries risk of Datura contamination.

**No safe recreational dose:** Published literature contains no evidence of a dose range at which *Datura* produces predictable, controllable, or tolerable effects. Every ingestion carries unpredictable potency risk. Fatalities have occurred with both intentional and accidental ingestion.

**Drug testing:** Standard urine immunoassay drug panels do NOT detect scopolamine, hyoscyamine, or atropine. Detection requires targeted GC-MS or LC-MS analysis, which is typically performed only in forensic or specialized toxicology contexts. A person impaired by *Datura* may pass a standard workplace drug screen [Ref 9, Ref 10 — case reports describe post-mortem detection by targeted methods only].

**Recovery:** No established cessation programs specific to *Datura* exist. The extreme aversiveness of the experience typically discourages repeat use [Ref 14]. No withdrawal management protocols identified in published literature.

---

## Legal Status

*Source: Erowid (web-retrieved, 2024) [Ref 18]; legal status is subject to change and this reflects available information at time of research.*

**United States — Federal:** *Datura* is **unscheduled and uncontrolled** at the federal level. The plant and its natural extracts are not listed under the Controlled Substances Act. Scopolamine and hyoscyamine are FDA-regulated pharmaceuticals when sold as medicines but are not DEA-scheduled when present in their natural plant source.

**United States — State level:**
- **Kansas:** *Datura stramonium* classified as a Schedule I controlled substance since 2008
- **Nevada:** Schedule I controlled substance (with exception for FDA-approved pharmaceutical formulations)
- **Louisiana:** Illegal when intended for human consumption; legal for "aesthetic, landscaping, or decorative purposes"
- **Connecticut:** Classified as a restricted drug except for FDA-approved preparations
- **New Jersey:** Distribution of Datura preparations is criminalized; the state may destroy discovered plants
- **Oklahoma:** Controlled under synthetic substance laws when used "as a drug"
- **Tennessee:** Not specifically restricted (only *Salvia divinorum* restricted)
- FLAG: This list may be incomplete. Recommend legal review for any jurisdiction-specific claims before publication.

**International:**
- **Australia:** Schedule 1 poison nationally (prohibited substance)
- **Canada:** Not scheduled; legal to grow and possess
- **United Kingdom:** Legal to grow and possess
- **India:** Legal; commonly used in religious contexts (associated with the deity Shiva)
- **Brazil:** *Datura suaveolens* (Angel's trumpet) is controlled
- **Norway:** Legal to grow; importation by mail prohibited
- **European Union:** No EU-wide scheduling of the plant; individual member states may have restrictions. Scopolamine and atropine are regulated as pharmaceuticals

**International treaty applicability:** Neither *Datura* nor its primary alkaloids (hyoscyamine, scopolamine, atropine) are listed in the schedules of the 1961 UN Single Convention on Narcotic Drugs, the 1971 UN Convention on Psychotropic Substances, or the 1988 UN Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. The alkaloids are controlled as pharmaceuticals in most jurisdictions but the plant itself is generally not internationally scheduled.

---

## Clinical Trials

A search of ClinicalTrials.gov for "Datura scopolamine hyoscyamine tropane alkaloid" returned **no active or completed trials** specifically investigating *Datura* as a substance [Ref — ClinicalTrials.gov search]. Scopolamine itself is the subject of numerous clinical trials (motion sickness, depression, anesthesia premedication), but these use pharmaceutical-grade scopolamine, not plant material, and are not directly relevant to the plant article.

**Relevant pharmaceutical context:** Scopolamine (as pharmaceutical hyoscine) is an FDA-approved medication for motion sickness (transdermal patch) and nausea/vomiting. It has demonstrated rapid antidepressant effects in clinical trials [Ref PMID 23364679 — JAMA Psychiatry 2013], though pharmaceutical scopolamine for depression remains investigational as of 2026. These approvals confirm the biological activity of the primary Datura alkaloid but do not represent Datura-specific research.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. Proceeding with standard research only.

---

## Gaps & Flags

### Safety-Critical Flags

1. **No established safe recreational dose for any preparation:** All dose data are derived from accidental/intentional poisoning case series. No controlled human dose-finding studies exist or could ethically be conducted. The generation agent should NOT present any dose range as "safe" or "common." [FLAG: Dose values not verified against published source — all come from poisoning cases]

2. **Alkaloid concentration data (specific mg/g values) not retrieved:** The Jakabová 2012 paper [Ref 4] contains the relevant HPLC/LC-MS concentration data by plant organ and species, but the full-text was not accessible; only abstract-level data was obtained. Specific numeric concentrations per gram dry weight should be sought in full-text before the generation agent uses them.

3. **Toxicity threshold not established:** Unlike many drugs, no formal LD50 has been established in humans. The EFSA ARfD of 0.016 μg/kg bw is based on heart rate changes (sub-toxic endpoint), not on the toxic/lethal threshold.

### Data Gaps

4. **Traditional/indigenous use — flag for human review:** Published PubMed searches retrieved no peer-reviewed ethnobotanical literature specifically documenting Native American ceremonial use of Datura. Information included in the History section draws on general ethnobotanical knowledge not sourced to primary literature retrieved in this session. **FLAG: Traditional-use section requires human editorial review and citation to authoritative ethnobotanical monographs (e.g., Moerman's *Native American Ethnobotany*, Schultes & Hofmann's *Plants of the Gods*).**

5. **Tolerance and dependence data:** Seed data from Curiosity v1 DB (tolerance buildup with repeated use; half-life 5 days; full reset 1.5 weeks) could **not be verified** against published primary sources in this research pass. No controlled studies on tolerance development for *Datura* alkaloids were found.

6. **Withdrawal syndrome:** No published literature specifically characterizing Datura/anticholinergic withdrawal was found. Cholinergic rebound is theoretically possible after chronic exposure but is not documented for *Datura* use.

7. **Drug test detection:** Standard drug panels do not detect tropane alkaloids. Specific detection by GC-MS/LC-MS confirmed in forensic case reports only. No published validated screening cutoffs for hyoscyamine/scopolamine in routine toxicology panels were found.

8. **Specific alkaloid concentrations by plant part (seeds vs. leaves):** The published literature consistently reports that seeds have highest concentrations, but specific mg/g values by part in *D. stramonium* were not retrieved from full texts. This gap is relevant to preparation-specific dose estimates.

9. **Brugmansia vs. Datura distinction:** The article should clearly distinguish *Datura* (annual herbs) from *Brugmansia* spp. (Angel's trumpets — woody shrubs/trees with pendulous flowers). They are often confused in public sources and in poisoning case reports. Both contain the same alkaloids but *Brugmansia* is not the subject of this article.

10. **Contaminant risk for commercial preparations:** *Datura* is not sold commercially as a recreational product; contamination risk is primarily agricultural (grain contamination). No commercial preparation–specific adulterant risk data found.

11. **Ayurvedic traditional use citations:** Traditional Indian use documented in Erowid sources but not retrieved from peer-reviewed primary literature. Flag for editorial sourcing to Ayurvedic pharmacopoeia references.

12. **Legal status confidence:** Legal status data from Erowid is web-retrieved and may not reflect recent legislative changes. Recommend verification against official state statutes before publication, particularly for Kansas, Nevada, Connecticut, New Jersey, and Australia.